Posts Tagged: Portfolio company

Zucara Therapeutics announced highly positive results from its proof-of-concept Phase 1b trial of ZT-01 in people with Type 1 diabetes (“T1D”). Please see the press release here. Why this news is important: This trial confirms ZT-01’s mechanism of action in restoring glucagon release in patients with T1D. First-in-class ZT-01, meaningfully restored glucagon release in nearly 90% of treated patients compared to placebo (p<0.0001). This therapy has the potential to become the first therapeutic to prevent hypoglycemia in people with insulin-dependent diabetes. Positive results from this trial will enable Zucara to further evaluate ZT-01 in a multi-center Phase 2 ... Read more